Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

The Journal of clinical investigation - 1 Mar 2004

Furumoto Katsuyoshi, Soares Luis, Engleman Edgar G, Merad Miriam

Abstract excerpt

Recent reports of tumor regression following delivery of autologous tumor antigen-pulsed DCs suggest that defective antigen presentation may play a key role in tumor escape. Here we show in two different murine tumor models, CT26 (colon adenocarcinoma) and B16 (melanoma), that the number and activation state of intratumoral DCs are critical factors in the host response to tumors. We used CCL20/macrophage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Cancer Vaccines
Share to Chemokines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemokines, CC

Share to Immunotherapy, Adoptive

Share to Macrophage Inflammatory Proteins

Share to Melanoma, Experimental

Share to Oligonucleotides

Source

Open in PubMed Open full text

Identifiers

PMID: 14991076
DOI: 10.1172/JCI19762
PMCID: PMC351319

Genes

CCL20
MIP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.PMID 14991076Read ↗

Tumor suppressive efficacy through augmentation of tumor-infiltrating immune cells by intratumoral injection of chemokine-expressing adenoviral vector.Semantic proximity Read ↗

<i>In situ</i> administration of cytokine combinations induces tumor regressionSemantic proximity Read ↗

In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.Semantic proximity Read ↗

Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells.Semantic proximity Read ↗

Activated dendritic cells delivered in tissue compatible biomatrices induce in-situ anti-tumor CTL responses leading to tumor regression.Semantic proximity Read ↗

CCR4 is critically involved in effective antitumor immunity in mice bearing intradermal B16 melanoma.Semantic proximity Read ↗

Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells.Semantic proximity Read ↗

Combined treatment of an intratumoral injection of dendritic cells and systemic chemotherapy (Paclitaxel) for murine fibrosarcoma.Semantic proximity Read ↗

Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo.Semantic proximity Read ↗

Enhanced migration of human dendritic cells expressing inducible CD40.Semantic proximity Read ↗

CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.